Abeona Therapeutics (NASDAQ:ABEO) Downgraded to Sell at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

Abeona Therapeutics Price Performance

ABEO opened at $7.36 on Tuesday. The company’s 50 day simple moving average is $7.49 and its two-hundred day simple moving average is $5.65. Abeona Therapeutics has a 1-year low of $2.83 and a 1-year high of $9.01. The firm has a market capitalization of $201.30 million, a price-to-earnings ratio of -2.85 and a beta of 1.49.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). On average, equities analysts anticipate that Abeona Therapeutics will post -1.83 earnings per share for the current fiscal year.

Institutional Trading of Abeona Therapeutics

Several institutional investors have recently made changes to their positions in ABEO. Simplex Trading LLC raised its position in shares of Abeona Therapeutics by 1,889.9% during the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 13,418 shares during the period. Barclays PLC raised its position in shares of Abeona Therapeutics by 100.0% during the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after buying an additional 185,638 shares during the period. Citigroup Inc. raised its position in shares of Abeona Therapeutics by 125.0% during the 3rd quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company’s stock valued at $1,894,000 after buying an additional 250,000 shares during the period. AIGH Capital Management LLC raised its position in shares of Abeona Therapeutics by 77.7% during the 3rd quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock valued at $4,779,000 after buying an additional 496,278 shares during the period. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at approximately $648,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.